Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Medical management of hypertrophic cardiomyopathy.

Naghi JJ, Siegel RJ.

Rev Cardiovasc Med. 2010 Fall;11(4):202-17. Review.

PMID:
21389910
2.

Management of hypertrophic cardiomyopathy in children.

Seggewiss H, Rigopoulos A.

Paediatr Drugs. 2003;5(10):663-72. Review.

PMID:
14510624
3.

Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression.

Keren A, Syrris P, McKenna WJ.

Nat Clin Pract Cardiovasc Med. 2008 Mar;5(3):158-68. doi: 10.1038/ncpcardio1110. Epub 2008 Jan 29. Review. Erratum in: Nat Clin Pract Cardiovasc Med. 2008 Nov;5(11):747.

PMID:
18227814
5.

The development of familial hypertrophic cardiomyopathy: from mutation to bedside.

Brouwer WP, van Dijk SJ, Stienen GJ, van Rossum AC, van der Velden J, Germans T.

Eur J Clin Invest. 2011 May;41(5):568-78. doi: 10.1111/j.1365-2362.2010.02439.x. Epub 2010 Dec 15. Review.

PMID:
21158848
6.

Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy.

Westermann D, Knollmann BC, Steendijk P, Rutschow S, Riad A, Pauschinger M, Potter JD, Schultheiss HP, Tschöpe C.

Eur J Heart Fail. 2006 Mar;8(2):115-21. Epub 2005 Oct 7.

7.

Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy.

Waldmüller S, Sakthivel S, Saadi AV, Selignow C, Rakesh PG, Golubenko M, Joseph PK, Padmakumar R, Richard P, Schwartz K, Tharakan JM, Rajamanickam C, Vosberg HP.

J Mol Cell Cardiol. 2003 Jun;35(6):623-36.

PMID:
12788380
8.

Advances in medical treatment of hypertrophic cardiomyopathy.

Hamada M, Ikeda S, Shigematsu Y.

J Cardiol. 2014 Jul;64(1):1-10. doi: 10.1016/j.jjcc.2014.02.022. Epub 2014 Apr 13. Review. Erratum in: J Cardiol. 2014 Oct;64(4):330.

9.

Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death.

Ostman-Smith I.

Fundam Clin Pharmacol. 2010 Oct;24(5):637-52. doi: 10.1111/j.1472-8206.2010.00869.x. Epub 2010 Aug 19. Review.

PMID:
20727015
10.

[Hypertrophic cardiomyopathy: DNA diagnosis, genetic counselling and the risk of sudden cardiac death].

Baars HF, Christiaans I, de Nijs PT, Cramer MJ, van Langen IM, Doevendans PA.

Ned Tijdschr Geneeskd. 2010;154:A698. Review. Dutch.

PMID:
20132578
12.

Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.

Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ.

J Am Coll Cardiol. 2005 Apr 19;45(8):1251-8.

13.

Mutation screening of the PTPN11 gene in hypertrophic cardiomyopathy.

Limongelli G, Hawkes L, Calabro R, McKenna WJ, Syrris P.

Eur J Med Genet. 2006 Sep-Oct;49(5):426-30. Epub 2006 Feb 3.

PMID:
16488201
14.

Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence.

Spoladore R, Maron MS, D'Amato R, Camici PG, Olivotto I.

Eur Heart J. 2012 Jul;33(14):1724-33. doi: 10.1093/eurheartj/ehs150. Epub 2012 Jun 19. Review.

PMID:
22719025
15.

The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening.

Christiaans I, Birnie E, van Langen IM, van Spaendonck-Zwarts KY, van Tintelen JP, van den Berg MP, Atsma DE, Helderman-van den Enden AT, Pinto YM, Hermans-van Ast JF, Bonsel GJ, Wilde AA.

Eur Heart J. 2010 Apr;31(7):842-8. doi: 10.1093/eurheartj/ehp539. Epub 2009 Dec 16.

PMID:
20019025
16.

[Sudden unexpected death--hypertrophic cardiomyopathy--genetically verified post-mortem].

Larsen MK, Lundemose JB, Jensen HK, Kristensen IB.

Ugeskr Laeger. 2009 Sep 21;171(39):2835-6. Danish.

PMID:
19811757
17.

Familial and sporadic hypertrophic myopathy: differences and similarities in a genotyped population. A long follow-up study.

Brito D, Richard P, Komajda M, Madeira H.

Rev Port Cardiol. 2008 Feb;27(2):147-73. English, Portuguese.

18.

Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy.

Christiaans I, Birnie E, Bonsel GJ, Mannens MM, Michels M, Majoor-Krakauer D, Dooijes D, van Tintelen JP, van den Berg MP, Volders PG, Arens YH, van den Wijngaard A, Atsma DE, Helderman-van den Enden AT, Houweling AC, de Boer K, van der Smagt JJ, Hauer RN, Marcelis CL, Timmermans J, van Langen IM, Wilde AA.

Eur Heart J. 2011 May;32(9):1161-70. doi: 10.1093/eurheartj/ehr092. Epub 2011 Apr 1.

PMID:
21459882
19.

[Sudden cardiac death in familial hypertrophic cardiomyopathy. Identification of high-risk patients].

Pellnitz C, Geier C, Perrot A, Dietz R, Osterziel KJ, Haverkamp W.

Dtsch Med Wochenschr. 2005 May 6;130(18):1150-4. Review. German.

PMID:
15856398
20.

[Evaluation of the risk of sudden death in hypertrophic cardiomyopathy].

Sadoul N, de Chillou C, Aliot E, McKenna WJ.

Arch Mal Coeur Vaiss. 1999 Apr;92 Spec No 1:65-73. Review. French.

PMID:
10326160

Supplemental Content

Support Center